Altimmune (ALT) EBITDA (2010 - 2026)
Altimmune (ALT) reported EBITDA of -$22.9 million for Q1 2026, down 16.6% year-over-year from -$27.4 million in Q1 2025, and up 16.18% on a QoQ basis from -$27.3 million in Q4 2025.
Altimmune (ALT) has 17 years of EBITDA data on file, last reported at -$22.9 million in Q1 2026.
- Quarterly EBITDA fell 16.6% year-over-year to -$22.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$91.3 million (down 1.35% YoY) and the FY2025 annual result came in at -$88.0 million, up 7.35% from the prior year.
- EBITDA grew to -$22.9 million in Q1 2026 per ALT's latest filing, from -$27.3 million in the prior quarter.
- Across five years, EBITDA topped out at -$16.1 million in Q2 2023 and bottomed at -$31.5 million in Q4 2023.
- The 5-year median for EBITDA is -$22.2 million (2025), against an average of -$22.3 million.
- The widest annual swing landed in 2022, when EBITDA advanced 29.4%; it then tumbled 52.86% in 2024.
- Tracing ALT's EBITDA over 5 years: stood at -$21.6 million in 2022, then plunged by 46.04% to -$31.5 million in 2023, then climbed by 26.06% to -$23.3 million in 2024, then retreated by 17.0% to -$27.3 million in 2025, then gained by 16.18% to -$22.9 million in 2026.
- Per Business Quant, the three latest ALT EBITDA figures stand at -$22.9 million (Q1 2026), -$27.3 million (Q4 2025), and -$19.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | -22.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.86 Mn |
| Dec 31, 2025 | -27.27 Mn |
| Sep 30, 2025 | -18.99 Mn |
| Jun 30, 2025 | -22.18 Mn |
| Mar 31, 2025 | -19.61 Mn |
| Dec 31, 2024 | -23.31 Mn |
| Sep 30, 2024 | -22.50 Mn |
| Jun 30, 2024 | -24.67 Mn |
| Mar 31, 2024 | -24.55 Mn |
| Dec 31, 2023 | -31.52 Mn |
| Sep 30, 2023 | -20.62 Mn |
| Jun 30, 2023 | -16.14 Mn |
| Mar 31, 2023 | -19.95 Mn |
| Dec 31, 2022 | -21.58 Mn |
| Sep 30, 2022 | -23.66 Mn |
| Jun 30, 2022 | -20.23 Mn |
| Mar 31, 2022 | -19.43 Mn |
| Dec 31, 2021 | -23.89 Mn |
| Sep 30, 2021 | -33.51 Mn |
| Jun 30, 2021 | -24.83 Mn |
| Mar 31, 2021 | -14.86 Mn |
| Dec 31, 2020 | -10.62 Mn |
| Sep 30, 2020 | -17.78 Mn |
| Jun 30, 2020 | -16.75 Mn |
| Mar 31, 2020 | -3.92 Mn |
| Dec 31, 2019 | -4.10 Mn |
| Sep 30, 2019 | -10.92 Mn |
| Jun 30, 2019 | -3.39 Mn |
| Mar 31, 2019 | -2.10 Mn |
| Dec 31, 2018 | -24.51 Mn |
| Sep 30, 2018 | -2.35 Mn |
| Jun 30, 2018 | -10.22 Mn |
| Mar 31, 2018 | -2.56 Mn |
| Dec 31, 2017 | -2.97 Mn |
| Sep 30, 2017 | -30.93 Mn |
| Jun 30, 2017 | -1.85 Mn |
| Mar 31, 2017 | -4.00 Mn |
| Dec 31, 2016 | -4.75 Mn |
| Sep 30, 2016 | -6.11 Mn |
| Jun 30, 2016 | -4.23 Mn |
| Mar 31, 2016 | -1.22 Mn |
| Dec 31, 2015 | -907,663.00 |
| Sep 30, 2015 | -1.62 Mn |
| Jun 30, 2015 | -1.93 Mn |
| Mar 31, 2015 | 1.20 Mn |
| Dec 31, 2014 | -2.59 Mn |
| Sep 30, 2014 | -3.96 Mn |
| Jun 30, 2014 | -1.13 Mn |
| Mar 31, 2014 | -2.36 Mn |
| Dec 31, 2013 | -5.02 Mn |
| Sep 30, 2013 | -3.15 Mn |
| Jun 30, 2013 | -1.44 Mn |
| Mar 31, 2013 | -1.04 Mn |
| Dec 31, 2012 | -1.36 Mn |
| Sep 30, 2012 | -1.72 Mn |
| Jun 30, 2012 | -1.46 Mn |
| Mar 31, 2012 | -1.59 Mn |
| Dec 31, 2011 | -1.08 Mn |
| Sep 30, 2011 | -3.02 Mn |
| Jun 30, 2011 | -3.08 Mn |
| Mar 31, 2011 | -4.54 Mn |
| Dec 31, 2010 | -7.25 Mn |
| Sep 30, 2010 | -3.36 Mn |
| Jun 30, 2010 | -5.54 Mn |